Introduction to IgA Nephropathy

EP: 1.Advancing IgA Nephropathy Care: Emerging Therapies, Unmet Needs, and Economic Considerations

Now Viewing

EP: 2.Introduction to IgA Nephropathy

EP: 3.Pathogenesis of IgA Nephropathy: The 4-Hit Cascade, A Proliferation-Inducing Ligand (APRIL), and cytokines

EP: 4.Diagnosing IgA Nephropathy

EP: 5.Signs and Symptoms of IgA Nephropathy

EP: 6.Challenges in Timely Identification of IgA Nephropathy

EP: 7.Clinical Impact of IgA Nephropathy and Quality of Life

EP: 8.Overview of Treatment Landscape for IgA Nephropathy: Standard of Care and KDIGO Guidelines

EP: 9.Current Treatments for IgA Nephropathy and the 4-Hit Cascade

EP: 10.Gaps in Patient Care for IgA Nephropathy

EP: 11.Emerging Anti-BAFF and Anti-APRIL Therapies

EP: 12.Emerging Therapies: Other Strategies and Important Considerations

EP: 13.The Promise of Emerging Therapies for IgA Nephropathy and Future KDIGO Guidelines

EP: 14.Sequencing and Individualizing Treatments for IgA Nephropathy

EP: 15.Measuring Success in IgA Nephropathy in Clinical Practice

EP: 16.Economic Impact of IgA Nephropathy for Patients

EP: 17.Early Diagnosis and Cost Mitigation in IgA Nephropathy

EP: 18.Cost Implications of Modulating IgA Nephropathy Disease Course

EP: 19.Patient-Reported Outcomes in the Treatment of IgA Nephropathy

EP: 20.Future Possibilities for Step Therapy in IgA Nephropathy Treatment

EP: 21.Key Managed Care Considerations for IgA Nephropathy Treatment

EP: 22.Key Economic Considerations in IgA Nephropathy: Progression to Chronic Kidney Disease

EP: 23.Closing Thoughts About IgA Nephropathy Treatment

IgA Nephropathy: Pathogenesis and the 4-Hit Cascade

IgA nephropathy (IgAN) is characterized by the deposition of IgA1-containing immune complexes in the glomerular mesangium. The pathogenesis follows a 4-hit cascade:

4-Hit Cascade

1. First hit - Aberrant IgA1 production: Production of galactose-deficient IgA1 (Gd-IgA1) due to abnormal O-glycosylation in the hinge region. This process involves defective activity of specific glycosyltransferases, particularly C1GalT1 and its chaperone Cosmc.
2. Second hit - Anti-glycan antibody production: Formation of autoantibodies (IgG or IgA) against the exposed GalNAc epitopes on Gd-IgA1.
3. Third hit - Immune complex formation: Circulating immune complexes form between Gd-IgA1 and anti-glycan antibodies.
4. Fourth hit - Mesangial deposition and inflammation: Deposition of these immune complexes in the mesangium, activating complement and mesangial cells, leading to inflammation, matrix expansion, and ultimately renal damage.

Role of APRIL and Cytokines

A PRoliferation-Inducing Ligand (APRIL):

• Member of the TNF family that promotes B-cell survival and differentiation
• Upregulated in patients with IgAN
• Stimulates IgA1-producing cells and may contribute to the overproduction of Gd-IgA1
• Binds to receptors TACI and BCMA, promoting plasma cell survival and IgA class switching

Key Cytokines in IgAN Pathogenesis:

• IL-6: Enhances IgA production and may affect glycosylation of IgA1
• TGF-β: Drives mesangial cell proliferation, extracellular matrix production, and fibrosis
• TNF-α: Promotes inflammation and mesangial cell activation
• BAFF: Works synergistically with APRIL to support B-cell survival and antibody production
• IL-4 and IL-5: Contribute to B-cell differentiation and IgA synthesis
• MCP-1/CCL2: Recruits inflammatory cells to the glomeruli

These cytokines create a proinflammatory environment that perpetuates kidney injury and progressive loss of renal function in patients with IgAN.